Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

Mawatari, Taro; Ikemura, Satoshi; Matsui, Gen; Iguchi, Takahiro; Mitsuyasu, Hiromichi; Kawahara, Shinya; Maehara, Masayuki; Muraoka, Ryoichi; Iwamoto, Yukihide; Nakashima, Yasuharu

doi:10.1016/j.bonr.2020.100275

Cited by 6 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, even in women whose BTMs were in the normal range or in the lower tertile, BMD still showed significant gain. There was not enough statistical power to assess antifracture efficacy in this study ( 294 ). Low baseline BTMs were found to be an independent predictor of inadequate response to risedronate ( 295 ).…”

Section: Part 2 the Use Of Btm In Clinical Practice: Potential Proble...mentioning

confidence: 97%

Bone Turnover Markers: Basic Biology to Clinical Applications

et al. 2022

View full text Add to dashboard Cite

Bone turnover markers (BTMs) are used widely, in both research and clinical practice. In the last 20 years, much experience has been gained in measurement and interpretation of these markers, which include commonly used bone formation markers bone alkaline phosphatase, osteocalcin, and procollagen I N-propeptide; and commonly used resorption markers serum C-telopeptides of type I collagen, urinary N-telopeptides of type I collagen and tartrate resistant acid phosphatase type 5b. BTMs are usually measured by enzyme-linked immunosorbent assay or automated immunoassay. Sources contributing to BTM variability include uncontrollable components (e.g., age, gender, ethnicity) and controllable components, particularly relating to collection conditions (e.g., fasting/feeding state, and timing relative to circadian rhythms, menstrual cycling, and exercise). Pregnancy, season, drugs, and recent fracture(s) can also affect BTMs. BTMs correlate with other methods of assessing bone turnover, such as bone biopsies and radiotracer kinetics; and can usefully contribute to diagnosis and management of several diseases such as osteoporosis, osteomalacia, Paget’s disease, fibrous dysplasia, hypophosphatasia, primary hyperparathyroidism, and chronic kidney disease-mineral bone disorder.

show abstract

Section: Part 2 the Use Of Btm In Clinical Practice: Potential Proble...mentioning

confidence: 97%

Bone Turnover Markers: Basic Biology to Clinical Applications

et al. 2022

View full text Add to dashboard Cite

show abstract

“…21 The same trend was observed with risedronate. 22 The mechanistic explanation was that bisphosphonate incorporation into the bone depends on the amount of active bone remodeling units. Specifically, higher turnover promotes bisphosphonate incorporation into the bone, resulting in a more pronounced BMD gain.…”

Section: Discussionmentioning

confidence: 99%

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone

Giveon,

Zacay,

Vered

et al. 2023

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Background: Teriparatide (TPTD) should be followed by an antiresorptive to maximize bone mineral density gain and anti-fracture protection. Infrequent zoledronic acid (ZOL) administration has demonstrated effectiveness. The duration of ZOL effect following TPTD is unknown. Objective: To evaluate the effect of ZOL on bone resorption marker in a post-TPTD versus ZOL-alone scenario in osteoporotic patients. Design: Retrospective cohort study. Methods: Patients treated with TPTD followed by ZOL (TPTD–ZOL) or with a single ZOL infusion were identified in the database of a tertiary referral center. Clinical and laboratory data, including C-terminal telopeptide of type I collagen (CTX) following ZOL treatment, were compared. Results: Twenty-six patients (93% women) treated with TPTD–ZOL and 41 with ZOL were comparable in age (median 70.1 versus 69.6 years, p = 0.6) and sex. Timing of CTX measurement post-ZOL was the same, median 1.0 year. CTX was lower following TPTD–ZOL (median 142.1 versus 184.2 pg/mL, p = 0.005). In a multivariable regression model (controlled for baseline characteristics), pretreatment with TPTD strongly predicted CTX <150 pg/mL, 1 year following ZOL (odds ratio = 7.5, 95% CI 1.3–58.1, p = 0.03). In a subgroup with sequential CTX measurements following one ZOL, significantly lower levels persisted in the TPTD–ZOL group for a median of 4.4 years follow-up. Conclusion: ZOL-administered sequential to TPTD yielded deeper and more prolonged bone resorption suppression than ZOL alone. Prospective data are needed to confirm whether in a sequential treatment scenario, subsequent ZOL dosing interval should be less frequent.

show abstract

“…In boys, increased tartrate-resistant acid phosphatase isoenzyme 5b (TRAP5b), another bone resorption marker, was positively related to WBBMD accrual. In adult studies, either elevated baseline or changes in CTX was a predictive marker for changes in BMD after therapeutic interventions in various causes of osteoporosis such as postmenopausal osteoporosis 15 or postkidney transplantation. 16 Taken together, therefore, decreased bone resorption markers may serve as a prognostic marker for lower BMD accrual in adolescents with 21OHD.…”

Section: Discussionmentioning

confidence: 99%

“…13 A growing body of evidence has demonstrated that increased OC or CTX is associated with decreased BMD in primary and secondary osteoporosis such as postmenopausal osteoporosis. 14 Furthermore, baseline or changes in BTMs also predict changes in BMD in observational and interventional studies 15,16 of osteoporosis. In 21OHD, only cross-sectional studies have examined the relationships between BTMs and BMD and found conflicting results.…”

Section: Introductionmentioning

confidence: 99%

Elevated bone turnover markers predict bone mineral density accrual in adolescents with 21‐hydroxylase deficiency

Wiromrat

Namphaisan

Wongsurawat

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

ContextPrognostic biomarkers for monitoring bone health in adolescents with 21‐hydroxylase deficiency (21OHD) are needed.ObjectivesTo assess associations between concentrations of baseline bone turnover markers (BTMs) including osteocalcin (OC) and type‐I collagen C‐terminal telopeptide (CTX) and changes in lumbar spine bone mineral density (LSBMD) in adolescents with classic 21OHD.Designs and patientsA retrospective‐prospective study of 33 adolescents with classic 21OHD who had baseline data for LSBMD, bone age (BA), and BTM concentrations.MethodsBTM concentrations were converted into z‐scores according to BA. We measured LSBMD at the follow‐up study visit and calculated the annual percentage change in LSBMD (%∆LSBMD).ResultsAt baseline, participants (55% female, 79% Tanner 5) had mean (±SD) age of 14.6 ± 3.6 years, BA 16.7 ± 2.9 years, and average glucocorticoid (GC) dose 17.3 ± 5.6 mg/m2/day of hydrocortisone equivalent. The mean follow‐up duration was 14.4 ± 5.6 months. Median (Q1–Q3) %∆LSBMD was 3.6% (0–8.5)/year. %∆LSBMD was similar among genders or 21OHD subtypes. Prednisolone versus hydrocortisone replacement resulted in lower %∆LSBMD (p = .004). %∆LSBMD was increased across tertiles of CTX z‐score (p = .014). %∆LSBMD correlated negatively with GC dose (p = .01) and positively with CTX and OC z‐scores (p < .01). In regression analyses, only CTX z‐score positively associated with %∆LSBMD (p = .003), adjusting for sex, BA, body mass index, testosterone, 25‐hydroxyvitamin D, and GC type and dose.ConclusionsHigher GC dose and the use of prednisolone were associated with decreased LSBMD accrual in adolescents with 21OHD. CTX z‐score independently associated with LSBMD accrual, suggesting its potential for prognostic bone biomarker.

show abstract

Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

Cited by 6 publications

References 30 publications

Bone Turnover Markers: Basic Biology to Clinical Applications

Bone Turnover Markers: Basic Biology to Clinical Applications

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone

Elevated bone turnover markers predict bone mineral density accrual in adolescents with 21‐hydroxylase deficiency

Contact Info

Product

Resources

About